New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 30, 2012
06:16 EDTEXELExelixis has replay of conference call
Conference call which discussed the company's plans to launch COMETRIQ in metastatic medullary thyroid cancer was held on November 29 at 5 pm a webcast replay is available. Webcast Link
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
09:22 EDTEXELOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quarter, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.
05:22 EDTEXELExelixis reports phase 3 pivotal trial of cobimetinib met secondary endpoint
Subscribe for More Information
September 25, 2015
18:49 EDTEXELExelixis up 16% after Phase 3 trial of cabozantinib met primary endpoint
In after-hours trading, shares are up 16% to $6.86.
18:16 EDTEXELExelixis says Phase 3 trial of cabozantinib met primary endpoint
Exelixis announced positive results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with renal cell carcinoma who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor. In July 2015, Exelixis disclosed that the trial met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients in the cabozantinib arm. Principal investigator Toni K. Choueiri, M.D. will present detailed data from the late-breaking METEOR abstract on Saturday, September 26, during the Presidential Session I at the European Cancer Congress 2015, which is being held September 25-29 in Vienna. The METEOR data and an accompanying editorial were also published today in The New England Journal of Medicine.
12:47 EDTEXELExelixis management to meet with William Blair
Meetings to be held in Europe on September 29-30 hosted by William Blair.
07:42 EDTEXELExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTEXELEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 23, 2015
07:18 EDTEXELExelixis to hold a webcast
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use